Loading organizations...
Loading organizations...
Alida Biosciences: Biotechnology company developing advanced tools for RNA modification analysis and epitranscriptomics for human health research.
Alida Biosciences is a San Diego, California-based biotechnology company that develops advanced genomic tools and platforms for high-throughput RNA modification analysis. The organization focuses specifically on the emerging field of epitranscriptomics, providing proprietary research kits and multiplexed assays to academic researchers, clinical scientists, and pharmaceutical companies. These technologies enable the evaluation of the RNA code beyond its primary sequence to help discover new biomarkers and therapeutic targets for human health and oncology. Operating with approximately 18 employees, the enterprise has secured $34.5 million in total capital, which includes a $27 million Series A financing round alongside $4 million in SBIR grants from the National Human Genome Research Institute. This business has attracted investments from prominent firms such as OrbiMed, Genoa Ventures, and F-Prime Capital. Alida Biosciences was founded in 2020 by Dingyin Tao, Gudrun Stengel, and Byron Purse.
Alida Biosciences has raised $7.5M across 1 funding round.
Alida Biosciences has raised $7.5M in total across 1 funding round.
Alida Biosciences has raised $7.5M in total across 1 funding round.
Alida Biosciences's investors include Genoa Ventures.
Alida Biosciences has raised $7.5M across 1 funding round. Most recently, it raised $7.5M Series A in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 12, 2024 | $7.5M Series A | Genoa Ventures |